Clinical trials: Tamoxifen
ER+ Breast Cancer
Tamoxifen Prediction Study in Patients With ER+ Breast Cancer
Adjuvant treatment with tamoxifen is the standard of care for women with estrogen receptor positive (ER+) breast cancer. Tamoxifen is converted to endoxifen, its active metabolite, via CYP2D6 enzymes.
- Trial name
- PREDICTAM (NCT05525481)
- Testing
- Tamoxifen
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center
Breast Cancer
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499083
- Testing
- therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Nebraska
Breast Neoplasms, mTor Protein
Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
Tamoxifen is a classical treatment for breast metastatic cancer after 3rd generation anti-aromatase hormonotherapy in adjuvant or in metastatic line.
- Trial name
- NCT01298713
- Testing
- Tamoxifen, Everolimus
- Where
- France
- Volunteers
- 111 people
- Sponsor
- ARCAGY/ GINECO GROUP
Ovarian Carcinoma
REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression
The objective of this randomized phase II is to evaluate the benefit of regorafenib for ovarian patients who reported a confirmed elevated CA-125 level under surveillance or bevacizumab, compared with tamoxifen.
- Trial name
- REGOVAR (NCT02584465)
- Testing
- Tamoxifen, Regorafenib
- Where
- 21 sites in France
- Volunteers
- 68 people
- Sponsor
- ARCAGY/ GINECO GROUP
Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer
This phase II trial studies how well pembrolizumab and tamoxifen with or without vorinostat work for the treatment of estrogen receptor positive breast cancer.
- Trial name
- NCT04190056
- Testing
- Pembrolizumab, Tamoxifen, Vorinostat
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, San Francisco
Carcinoma, Intraductal, Noninfiltrating, Recurrence, Local Neoplasm
Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up
The aim of the study is to evaluate whether tamoxifen at a low dose of 5mg/d reduces in the long term the incidence of invasive breast cancer and ductal carcinoma in situ, DCIS (DIN 1c, 2, 3) of the breast, in woman operated for…
- Conditions
- Carcinoma, Intraductal, Noninfiltrating, Recurrence, Local Neoplasm, Breast Neoplasms, Atypical Hyperplasia
- Trial name
- TAM-01 (NCT01357772)
- Testing
- Tamoxifen
- Where
- 14 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Andrea DeCensi
Early-stage Breast Cancer
Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
Primarily, this clinical investigation compared the efficacy of cyclophosphamide + methotrexate + fluorouracil chemotherapy vs. goserelin + tamoxifen treatment in terms of prognosis (disease-free survival, overall survival) in…
- Trial name
- NCT00309478
- Testing
- Cyclophosphamide, Methotrexate, Fluorouracil implant
- Volunteers
- 1,099 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Breast Cancer, Stage IV Breast Cancer
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight cancer by blocking the use of estrogen by tumor cells.
- Trial name
- NCT01124695
- Testing
- tamoxifen
- Where
- 294 sites in United States, Canada and 1 more
- Volunteers
- 124 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Cancer
Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) Users
The propose of this trial is to assess the effect of low dose tamoxifen for breast cancer prevention in HRT (Hormone Replacement Therapy)users.
- Trial name
- HOT (NCT01579734)
- Testing
- Tamoxifen
- Where
- Italy
- Volunteers
- 1,884 people
- Sponsor
- European Institute of Oncology
Breast Cancer
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for breast cancer.
- Trial name
- NCT00004125
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- 48 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer Female, Hormone Receptor Positive Tumor
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer
Phase II trial of 2 years of standard adjuvant endocrine therapy after low risk hormone receptor positive, HER2 negative, node negative breast cancer in women older than 50 at diagnosis.
- Trial name
- LALEAST (NCT03917082)
- Testing
- Tamoxifen Citrate
- Where
- Canada
- Volunteers
- 290 people
- Sponsor
- British Columbia Cancer Agency
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
The purpose of the Phase Ib is to: 1. determine the recommended dose of LEE011 in combination with a standard dose of letrozole as well as to provide additional safety and anti-tumor activity data in Asian non-Japanese patients…
- Trial name
- NCT02333370
- Testing
- LEE011, Letrozole, Tamoxifen
- Where
- 15 sites in Hong Kong, Japan and 1 more
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
HR Positive HER2 Negative Advanced Breast Cancer
A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy
To explore the efficacy and safety of Chidamide combined with endocrine for maintenance therapy after first-line chemotherapy for HR+/HER2- breast cancer
- Trial name
- NCT05890287
- Testing
- Chidamide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Prostate Cancer, Erectile Dysfunction
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
The purpose of this study is to determine if a combination of neoadjuvant dutasteride and bicalutamide has the same efficacy and less toxicity than standard treatment with an LHRH agonist and bicalutamide for prostate…
- Conditions
- Prostate Cancer, Erectile Dysfunction, Lower Urinary Tract Symptoms
- Trial name
- NCT00866554
- Testing
- administration of a LHRH agonist and Bicalutamide, administration of Bicalutamide, Dutasteride and Tamoxifen
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- CHU de Quebec-Universite Laval
Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer
Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
This study aims to enroll premenopausal patients, with early breast cancer who are non-low-risk and hormone receptor-positive and have undergone prior surgical intervention at the Breast Cancer Center of Sun Yat-sen Memorial…
- Conditions
- Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer, Breast Cancer Patients at Intermediate to High Risk, Ovarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or Torimefen
- Trial name
- NCT05801705
- Testing
- Aromatase inhibitor, ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist), Tamoxifen
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer, Neoadjuvant Endocrine Therapy
Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia
Neoadjuvant Endocrine Therapy for pre- and postmenopausal women with T4 Nany or TanyN2-3 estrogen receptor (ER) -positive, progrsteron receptor (PR) -positive and HER2 negative breast cancer. Real Clinical Practice in Russia.
- Trial name
- NEMO (NCT05800197)
- Testing
- Tamoxifen 20mg, Anastrozole 1mg, Letrozole 2.5mg
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Breast Cancer
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.
The HOBOE study was amended in November 2009, and, after reaching enrollment of the first 500 patients, the study began recruiting premenopausal patients only.
- Trial name
- HOBOE (NCT00412022)
- Testing
- tamoxifen, triptorelin, letrozole
- Where
- 20 sites in Italy
- Volunteers
- 1,294 people
- Sponsor
- National Cancer Institute, Naples
HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Although randomized controlled trials (RCTs) provide evidence of efficacy, generalization of these results to patients in the real-world setting is challenging, given RCTs are conducted in highly selected patient populations.
- Trial name
- Treat ER+ight (NCT02753686)
- Testing
- Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
- Where
- 25 sites in Canada
- Volunteers
- 440 people
- Sponsor
- Novartis Pharmaceuticals
Endometrial Cancer Stage III, Endometrial Cancer Stage IV
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy
- Conditions
- Endometrial Cancer Stage III, Endometrial Cancer Stage IV, Endometrial Cancer Recurrent
- Trial name
- PROMOTE (NCT03621904)
- Testing
- Hormonal Antineoplastics
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Radboud University Medical Center
Breast Cancer
Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women
The objective of this study is to compare the curative effects in patients under the age of 35 with hormone receptor positive breast cancer and high recurrent risk factors including large tumor or metastatic lymph nodes…
- Trial name
- ASPAIT (NCT02914158)
- Testing
- Goserelin, Tamoxifen, Aromatase Inhibitors
- Where
- 25 sites in China
- Volunteers
- 680 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University